Top

Published in:

01-12-2016 | Original Article

Where are we going? Translational research in hepatic encephalopathy

Authors: Piero Amodio, Sara Montagnese, Kevin Mullen, James G. Orr, Hendrik Vilstrup

Published in: Metabolic Brain Disease | Issue 6/2016

Abstract

Translational medicine, rather than being a unidirectional clinical utilization of basic research discoveries, should be a bidirectional process of cross-fertilization between basic science, medical knowledge and clinical utilization. While steps and processes differ across these branches of research, clear language and proper definitions are prerequisites for effective interaction of researchers to facilitate knowledge development. With respect to Hepatic Encephalopathy, at first glance the areas which require development are around prevention, both to reduce the risk of relapse following an episode of overt HE and to reduce the risk of the first episode of HE. In addition, shortening the duration of episodes of overt HE may also be relevant. Comparisons of treatments and combinations of treatments, acting by different but potentially synergistic mechanisms, are reasonable targets for both basic and applied research.

Agrawal A, Sharma BC, Sharma P, Sarin SK (2012) Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am.J.Gastroenterol. 107:1043–1050. doi:10.1038/ajg.2012.113 CrossRefPubMed

Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, Hafeezullah M, Bell DE, Sterling RK, Stravitz RT, Fuchs M, Luketic V, Sanyal AJ (2011) Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 140:478–487. doi:10.1053/j.gastro.2010.08.061 CrossRefPubMed

Bajaj JS, Schubert CM, Heuman DM, Wade JB, Gibson DP, Topaz A, Saeian K, Hafeezullah M, Bell DE, Sterling RK, Stravitz RT, Luketic V, White MB, Sanyal AJ (2010) Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology 138:2332–2340. doi:10.1053/j.gastro.2010.02.015 CrossRefPubMedPubMedCentral

Berni E, Bannister C, Poole CD, Conway P, Nanuwa K, Currie CJ (2014) PWE-154 the first evaluation of the relationship between the chronic liver disease questionnaire and the Eq-5d index in hepatic encephalopathy patients treated with rifaximin-a. Gut 63:A192. doi:10.1136/gutjnl-2014-307263.414 CrossRef

Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP (2010) Rifaximin treatment in hepatic encephalopathy. N.Engl.J.Med 362:1071–1081. doi:10.1056/NEJMoa0907893 CrossRefPubMed

Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J.Health Econ. 21:271–292CrossRefPubMed

Briggs A, Claxton K, Sculpher M (2006) Decision Modelling for Health Eonomic Evaluation Oxford. University Press, New York

Butterworth RF, Norenberg MD, Felipo V, Ferenci P, Albrecht J, Blei AT (2009) Experimental models of hepatic encephalopathy: ISHEN guidelines. Liver Int 29:783–788. doi:10.1111/j.1478-3231.2009.02034.x CrossRefPubMed

Campagna F, Montagnese S, Schiff S, Biancardi A, Mapelli D, Angeli P, Poci C, Cillo U, Merkel C, Gatta A, Amodio P (2014) Cognitive impairment and electroencephalographic alterations before and after liver transplantation: what is reversible? Liver Transpl 20:977–986. doi:10.1002/lt.23909 CrossRefPubMed

Campagna F, Montagnese S, Schiff S, Ruzzoli M, Biancardi A, Iannizzi P, Pujatti PL, Angeli P, Gatta A, Merkel C, Leandro G, Mapelli D, Amodio P (2015) Confounders in the detection of minimal hepatic encephalopathy: a neuropsychological and quantified EEG study. Liver Int 35:1524–1532. doi:10.1111/liv.12635 CrossRefPubMed

Cordoba J, Ventura-Cots M, Simon-Talero M, Amoros A, Pavesi M, Vilstrup H, Angeli P, Domenicali M, Gines P, Bernardi M, Arroyo V (2014) Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J.Hepatol. 60:275–281. doi:10.1016/j.jhep.2013.10.004 CrossRefPubMed

Courson A, Jones GM, Twilla JD (2015) Treatment of acute hepatic encephalopathy: comparing the effects of adding rifaximin to lactulose on patient outcomes. J.Pharm.Pract. doi:10.1177/0897190014566312 PubMed

DeMaria AN (2013) Translational research? J.Am.Coll.Cardiol. 62:2342–2343. doi:10.1016/j.jacc.2013.11.008 CrossRefPubMed

Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, New York

Galen RS, Gambino SR (1975) Beyond normality: the predictive value and efficiency of medical diagnoses. Wiley, New York

Gray AM, Clarke PM, Wostenholme IL, & wordsworth S (2011) Applied Methods of Cost-Effectiveness Analysis in Health CareOxford University Press, Oxford

Goel A, Gupta M, Aggarwal R (2014) Gut microbiota and liver disease. J.Gastroenterol.Hepatol. 29:1139–1148. doi:10.1111/jgh.12556 CrossRefPubMed

Grundy SM, Pasternak R, Greenland P, Smith Jr S, Fuster V (1999) AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J.Am.Coll.Cardiol 34:1348–1359CrossRefPubMed

Kircheis G, Knoche A, Hilger N, Manhart F, Schnitzler A, Schulze H, Haussinger D (2009) Hepatic encephalopathy and fitness to drive. Gastroenterology 137:1706–1715. doi:10.1053/j.gastro.2009.08.003 CrossRefPubMed

Kjeldsen S, Feldman RD, Lisheng L, Mourad JJ, Chiang CE, Zhang W, Wu Z, Li W, Williams B (2014) Updated national and international hypertension guidelines: a review of current recommendations. Drugs 74:2033–2051CrossRefPubMedPubMedCentral

Montagnese S, Amato E, Schiff S, Facchini S, Angeli P, Gatta A, Amodio P (2012) A patients’ and caregivers’ perspective on hepatic encephalopathy. Metab Brain Dis 27:567–572. doi:10.1007/s11011-012-9325-7 CrossRefPubMed

Montagnese S, Jackson C, Morgan MY (2007) Spatio-temporal decomposition of the electroencephalogram in patients with cirrhosis. J.Hepatol. 46:447–458. doi:10.1016/j.jhep.2006.10.015 CrossRefPubMed

Morris S, Devlin N, Parkin D (2007) Economic analysis in health Care. Wiley, Chichester

NICE. Rifaximin for preventing episodes of overt hepatic encephalopathy. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ta337/documents Published March 2015. Accessed 05/05/2015.

Niessen CM, Krieg T (2014) Clinician scientists and PhDs: the need to connect basic research to translational medicine-a personal experience. J.Invest Dermatol. 134:295–298. doi:10.1038/jid.2013.466 CrossRefPubMed

Orr JG, Homer T, Ternent L, Newton J, McNeil CJ, Hudson M, Jones DE (2014) Health related quality of life in people with advanced chronic liver disease. J.Hepatol. 61:1158–1165. doi:10.1016/j.jhep.2014.06.034 CrossRefPubMed

Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R (2007) Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45:549–559. doi:10.1002/hep.21533 CrossRefPubMed

Riggio O, Ridola L, Pasquale C, Nardelli S, Pentassuglio I, Moscucci F, Merli M (2011) Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. Clin.Gastroenterol.Hepatol. 9:181–183. doi:10.1016/j.cgh.2010.10.002 CrossRefPubMed

Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS, Jr., Alexeeva O, Zupanets IA, Grinevich V, Baranovsky A, Dudar L, Fadieienko G, Kharchenko N, Klaryts'ka I, Morozov V, Grewal P, McCashland T, Reddy KG, Reddy KR, Syplyviy V, Bass NM, Dickinson K, Norris C, Coakley D, Mokhtarani M, & Scharschmidt BF(2014) Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology, 59:1073–1083. doi: 10.1002/hep.26611 CrossRefPubMedPubMedCentral

Roman E, Cordoba J, Torrens M, Torras X, Villanueva C, Vargas V, Guarner C, Soriano G (2011) Minimal hepatic encephalopathy is associated with falls. AmJGastroenterol 106:476–482. doi:10.1038/ajg.2010.413

Rowen D, Brazier J, Roberts J (2009) Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health QualLife Outcomes 7:27. doi:10.1186/1477-7525-7-27 CrossRef

Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen JM, Huang S, Merchant K, Bortey E, Forbes WP (2011) Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment.Pharmacol.Ther. 34:853–861. doi:10.1111/j.1365-2036.2011.04808.x CrossRefPubMed

Schiff S, Vallesi A, Mapelli D, Orsato R, Pellegrini A, Umilta C, Gatta A, Amodio P (2005) Impairment of response inhibition precedes motor alteration in the early stage of liver cirrhosis: a behavioral and electrophysiological study. Metab Brain Dis 20:381–392. doi:10.1007/s11011-005-7922-4 CrossRefPubMed

Schomerus H, Hamster W (2001) Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis 16:37–41CrossRefPubMed

Sharma BC, Sharma P, Agrawal A, Sarin SK (2009) Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 137(885–91):891. doi:10.1053/j.gastro.2009.05.056

Sotil EU, Gottstein J, Ayala E, Randolph C, Blei AT (2009) Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation. Liver Transpl 15:184–192. doi:10.1002/lt.21593 CrossRefPubMed

Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P (2014) Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the american association for the study of liver diseases and the european association for the study of the liver. Hepatology 60:715–735. doi:10.1002/hep.27210 CrossRefPubMed

Weissenborn K, Giewekemeyer K, Heidenreich S, Bokemeyer M, Berding G, Ahl B (2005) Attention, memory, and cognitive function in hepatic encephalopathy. Metab Brain Dis 20:359–367. doi:10.1007/s11011-005-7919-z CrossRefPubMed

Title: Where are we going? Translational research in hepatic encephalopathy
Authors: Piero Amodio
Sara Montagnese
Kevin Mullen
James G. Orr
Hendrik Vilstrup
Publication date: 01-12-2016
Publisher: Springer US
Published in: Metabolic Brain Disease / Issue 6/2016
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-015-9728-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Where are we going? Translational research in hepatic encephalopathy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

Glycine and hyperammonemia: potential target for the treatment of hepatic encephalopathy

Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure

Agomelatine reduces brain, kidney and liver oxidative stress but increases plasma cytokine production in the rats with chronic mild stress-induced depression

1H and 31P magnetic resonance spectroscopy in a rat model of chronic hepatic encephalopathy: in vivo longitudinal measurements of brain energy metabolism

Pyridoxine-dependent epilepsy: report on three families with neuropathology

Current state of knowledge of hepatic encephalopathy (part III): non-absorbable disaccharides